Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
SN

NYSE · SNN

Smith & Nephew plc

Healthcare · Medical - Devices

$27.56

Down-$0.22 (-0.79%)

Updated Sep 20, 2026, 1:01 PM

SID Score

4.2/10

Composite research score

Smart Money

56/100

Neutral

Market cap
14.34B
P/E ratio
29.03
Dividend yield
2.76%
52-week range
$27.23 – $37.51
Volume
1.45M
Avg. volume
605.67K

Price performance

SNN price history

1M range · 19 trading sessions · Daily adjusted prices

SNN closed at $27.56 after 19 trading sessions, down 6.95% for the selected period.

Last close
$27.56
Period change
-6.95%
Period low
$27.50
Period high
$29.62
Daily close
View OHLC price history
SNN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$27.55$27.655$27.43$27.561.45M
Sep 17, 2026$27.80$27.825$27.50$27.781.17M
Sep 16, 2026$27.90$28.10$27.765$27.80871.35K
Sep 15, 2026$28.12$28.19$27.955$28.011.67M
Sep 14, 2026$28.41$28.505$28.19$28.401.45M
Sep 11, 2026$27.87$27.91$27.23$27.501.14M
Sep 10, 2026$27.96$28.02$27.555$27.621.69M
Sep 9, 2026$27.77$27.94$27.56$27.801.97M
Sep 8, 2026$29.16$29.16$27.569$27.873.64M
Sep 4, 2026$28.77$29.015$28.69$28.87851.04K
Sep 3, 2026$29.03$29.24$28.48$28.693.2M
Sep 2, 2026$28.61$29.155$28.58$28.663.38M
Sep 1, 2026$29.63$29.69$28.90$28.972.78M
Aug 31, 2026$29.21$29.21$28.76$28.764.3M
Aug 28, 2026$28.89$29.025$28.75$28.971.49M
Aug 27, 2026$29.14$29.34$29.04$29.131.11M
Aug 26, 2026$29.29$29.435$29.155$29.302.38M
Aug 25, 2026$29.34$29.37$29.11$29.221.83M
Aug 24, 2026$29.43$29.735$29.40$29.621.05M

Latest SNN news

The latest Smart Investors Daily articles mentioning SNN.

Stock researchCompany · Overview

SNN research

Overview

Company profile and research snapshot.

Company profile

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$36.75
Implied upside
—
Analysts
—
SNN recent ratings
DateFirmRatingTarget
Jul 21, 2026Shore CapitalBuy—
Jun 29, 2026RBC Capital MarketsSector Perform—
Jun 11, 2026DeutscheHold—
Jun 10, 2026RBC Capital MarketsSector Perform—
May 21, 2026JefferiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

S.N. Nuclearelectrica (BVB:SNN) Stock Gets Fair Value Boost As Analysts Rework Growth Assumptions

The latest analyst work on S.N. Nuclearelectrica centers on a revised price target of RON 49.75, up from RON 44.80. This sets a new reference point for how the stock is being valued. This change reflects a mix of optimism and caution in recent commentary, with research tying the new target to refreshed assumptions rather than a single event. As you read on, you will see how this evolving narrative might shape the way you track S.N. Nuclearelectrica from here. Stay updated as the Fair Value...

Yahoo · Sep 16, 2026

Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the results of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to

Yahoo · Sep 15, 2026

Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds

Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the pricing of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By